Susan Salter, MD
Radiation Oncology · Birmingham, ALNPI 1376579169
Payments from drug & device makers
Across 15 payments — averaging $19.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Varian Medical Systems, Inc.$47
- Novartis$36
- Myriad Genetic Laboratories, Inc.$35
- Tactile Systems Technology Inc$33
- Ambu Inc.$29
- Isoray, Inc$20
- plus $101 from 6 others
What the payments were for
- Food & beverage$300100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Varian Medical Systems, Inc. | 1 | $47 |
| Novartis | 2 | $36 |
| Myriad Genetic Laboratories, Inc. | 2 | $35 |
| Tactile Systems Technology Inc | 2 | $33 |
| Ambu Inc. | 1 | $29 |
| Isoray, Inc | 1 | $20 |
| Olympus America Inc. | 1 | $20 |
| Sanofi | 1 | $18 |
| Novo Nordisk | 1 | $17 |
| Siemens Medical Solutions USA, Inc. | 1 | $16 |
| Progenics Pharmaceuticals, Inc. | 1 | $15 |
| Bayer | 1 | $15 |
How this compares
$300 in reported general payments places this provider in the 25th percentile of 87 radiation oncology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Letrozole | 163 | $4,376 |
| Raloxifene Hcl | 52 | $2,257 |
| Estradiol | 21 | $2,244 |
| Tamoxifen Citrate | 35 | $1,693 |
| Exemestane | 11 | $1,590 |
| Oxycodone Hcl | 30 | $1,062 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 25 | $1,008 |
| Lidocaine Hcl ViscousLidocaine Hcl | 48 | $865 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 18 | $758 |
| Oxybutynin Chloride | 49 | $751 |
| Anastrozole | 15 | $659 |
| Sucralfate | 26 | $651 |
| Dexamethasone | 20 | $316 |
| Mirtazapine | 15 | $186 |
| Tamsulosin Hcl | 15 | $141 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Birmingham
- Andrew McDonaldBirmingham$256K
- Christopher WilleyBirmingham$213K
- Drexell BoggsBirmingham$161K
- Samuel MarcromBirmingham$146K
- Michael DobelbowerBirmingham$98K
- Corey SpeersBirmingham$36K
- Adam KoleBirmingham$11K
- William EnnisBirmingham$6K
- John StahlBirmingham$3K
- Omer BurnettBirmingham$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.